ADVERSE SIDE EFFECTS OF TUBERCULOSIS ETIOTROPIC TREATMENT REGIMENS CONTAINING THE NEW ANTI-TUBERCULOSIS DRUG OF SQ109

ADVERSE SIDE EFFECTS OF TUBERCULOSIS ETIOTROPIC TREATMENT REGIMENS CONTAINING THE NEW ANTI-TUBERCULOSIS DRUG OF SQ109

.

Saved in:

Bibliographic Details
Main Author:	S. E. Borisov
Format:	Article
Language:	Russian
Published:	New Terra Publishing House 2018-08-01
Series:	Туберкулез и болезни лёгких
Online Access:	https://www.tibl-journal.com/jour/article/view/1156
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

EFFICIENCY AND SAFETY OF CHEMOTHERAPY REGIMEN WITH SQ109 IN THOSE SUFFERING FROM MULTIPLE DRUG RESISTANT TUBERCULOSIS
by: S. E. Borisov, et al.
Published: (2018-04-01)

Сlinical and economic evaluation of various etiotropic chemotherapy regimens in patients with respiratory tuberculosis with multidrug and extensively drug resistance
by: N. Yu. Nikolenko, et al.
Published: (2023-07-01)

TO DISCONTINUE OR TO WAIT?: INDICATIONS FOR DISCONTINUATION OF ANTI-TUBERCULOSIS DRUGS DUE TO ADVERSE EVENTS
by: D. A. Ivаnovа, et al.
Published: (2018-03-01)

Heterogeneity of Mycobacterium tuberculosis drug resistance in respect of pharmacokinetics of anti-tuberculosis drugs as a basis for individual treatment regimen
by: S. A. Popov, et al.
Published: (2015-04-01)

Neurotoxic Side Effects of Antimicrobial and Anti-Tuberculosis Drugs
by: G. N. Mozhokina, et al.
Published: (2020-08-01)

Unfavorable side effects to first line anti-tuberculosis drugs
by: N. A. Stepanova, et al.
Published: (2016-05-01)

Adverse events reported with BPaL and BPaLM regimens in drug-resistant tuberculosis
by: Kannan Sridharan, et al.
Published: (2025-08-01)

Safety of treatment regimens in multiple drug resistant tuberculosis patients compiled as per the new WHO recommendations as of 2019
by: D. A. Ivanova, et al.
Published: (2020-02-01)

FREQUENCY AND CHARACTERISTICS OF ADVERSE REACTIONS TO SECOND LINE ANTI-TUBERCULOSIS DRUGS IN THOSE ILL WITH MULTIPLE DRUG RESISTANT TUBERCULOSIS
by: A. A. Toktogonova
Published: (2017-11-01)

Frequency and characteristics of adverse events caused by anti-tuberculosis drugs in pulmonary tuberculosis patients with diabetes myelitis
by: O. G. Komissarova, et al.
Published: (2020-03-01)

Genetic Aspects of Mycobacterium Tuberculosis Resistance to New Anti-Tuberculosis Drugs
by: A. V. Kukurika, et al.
Published: (2023-08-01)

A CLINICAL CASE OF EFFECTIVE TREATMENT OF EXTENSIVE DRUG RESISTANCE TUBERCULOSIS WITH NEW ANTI-TUBERCULOSIS DRUGS
by: M. V. Pаvlovа, et al.
Published: (2018-01-01)

Clinical efficacy and computed tomography diagnostic value of bedaquiline‐containing regimens in the treatment of drug‐resistant pulmonary tuberculosis
by: Saiduo Liu, et al.
Published: (2024-09-01)

Treatment outcomes of regimens containing delamanid within therapy of multiple and extensive drug resistant tuberculosis in the Russian Federation
by: A. O. Maryandyshev, et al.
Published: (2019-12-01)

PROFILE AND RISK FACTORS OF ADVERSE REACTIONS IN NEW TUBERCULOSIS CASES RECEIVING TREATMENT
by: D. A. Ivаnovа, et al.
Published: (2017-06-01)

ECONOMIC FEASIBILITY OF NEW CHEMOTHERAPY REGIMENS FOR TREATMENT OF TUBERCULOSIS PATIENTS WITH EXTENSIVE DRUG RESISTANCE
by: I. A. Vasilyeva, et al.
Published: (2018-07-01)

Designing molecular diagnostics for current tuberculosis drug regimens
by: Sophia B. Georghiou, et al.
Published: (2023-12-01)

Modern Russian Etiotropic Antiinfluenza Drugs
by: F. I. Ershov, et al.
Published: (2020-05-01)

Efficacy and safety of an innovative short-course regimen containing clofazimine for treatment of drug-susceptible tuberculosis: a clinical trial
by: Xubin Zheng, et al.
Published: (2023-12-01)

Contemporary approaches to the search for active drugs and chemotherapy regimens for tuberculosis treatment
by: T. K. Lugovkinа, et al.
Published: (2020-07-01)

Immediate and Postponed Results of Short-Course Chemotherapy Regimens Containing Bedaquiline in Tuberculosis Patients with Multiple Drug Resistance
by: P. N. Golubchikov, et al.
Published: (2023-08-01)

TREATMENT OF TUBERCULOSIS PATIENTS WITH EXTENSIVE DRUG RESISTANCE USING NEW ANTI-TUBERCULOSIS DRUGS IN THE CIVILIAN COMMUNITY OF ARKHANGELSK REGION
by: Anastasiya I. Gayda, et al.
Published: (2018-08-01)

Ensuring the involvement of children in the evaluation of new tuberculosis treatment regimens.
by: William J Burman, et al.
Published: (2008-08-01)

EXPERIENCE OF TREATING MULTIPLE AND EXTENSIVE DRUG RESISTANT TUBERCULOSIS WITH NEW REGIMENS IN BELARUS REPUBLIC
by: E. M. Skryagina, et al.
Published: (2018-09-01)

Toxicity of treatment regimens for drugresistant tuberculosis.
by: G. N. Mozhokina, et al.
Published: (2022-03-01)

Comparative analysis of eﬃcacy and safety of various anti-tuberculosis therapy regimens in patients with MDR/XDR tuberculosis
by: E. P. Myshkova, et al.
Published: (2022-06-01)

Diagnostic dilemma of a new endobronchial lesion in a patient on anti-tuberculosis regimen: unveiling tuberculosis immune reconstitution inflammatory syndrome
by: Ming Ren Toh, et al.
Published: (2025-05-01)

Safety of new tuberculosis treatment regimens and compliance with these regimens according to data from the Republic of Kazakhstan
by: Zh. T. Zhandauletova, et al.
Published: (2023-03-01)

An overview of the new rifampicin-resistant tuberculosis regimens available at decentralised drug-resistant tuberculosis sites for persons older than six years
by: Madeleine Muller
Published: (2020-02-01)

Adverse Drug Reactions in Multidrug-resistant Tuberculosis Patients on Longer Bedaquiline-based Regimen at a Tertiary Care Center in Mumbai
by: Abhishek Saini, et al.
Published: (2025-07-01)

Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model.
by: Emily A Kendall, et al.
Published: (2017-01-01)

Lifesaving, cost-saving: Innovative simplified regimens for drug-resistant tuberculosis.
by: Aastha Gupta, et al.
Published: (2022-01-01)

Non-Injection Chemotherapy Regimens for Drug Resistant Tuberculosis in Children and Adolescents
by: V. A. Aksenova, et al.
Published: (2023-12-01)

Recent advancements in tuberculosis (TB) treatment regimens
by: Shyamala Ravikoti, et al.
Published: (2025-02-01)

AN INTEGRATED SYSTEM FOR PREDICTION OF ADVERSE OUTCOME DURING ANTI-TUBERCULOSIS TREATMENT
by: Tatiana V. Pianzova, et al.
Published: (2016-03-01)

Nephrotoxic characteristics of anti-tuberculosis drugs
by: G. N. Mozhokina, et al.
Published: (2019-11-01)

Clinical Efficacy and Safety of Clofazimine in Treatment Regimens for Drug Resistant Tuberculosis (Meta-Analysis)
by: A. I. Gayda, et al.
Published: (2024-05-01)

A NEW DRUG IN THE TREATMENT OF TUBERCULOSIS
by: article Editorial
Published: (2024-09-01)

The Effectiveness and Safety of Fluoroquinolone-Containing Regimen as a First-Line Treatment for Drug-Sensitive Pulmonary Tuberculosis: A Systematic Review and Meta-Analysis.
by: Hyun Woo Lee, et al.
Published: (2016-01-01)

Establishing the Safety and Efficacy of Bedaquiline-Containing Regimen for the Treatment of Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
by: Muhammad Candragupta Jihwaprani, et al.
Published: (2024-01-01)